Goldman Sachs
VERV

Goldman Sachs’s Verve Therapeutics VERV Stock Holding History

Goldman Sachs’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,482,642
Closed -$16.7M – 6665
2025
Q2 		$16.7M Buy
1,482,642
+69,524
+5% +$396K ﹤0.01% 2288
2025
Q1 		$6.46M Buy
1,413,118
+671,939
+91% +$4.5M ﹤0.01% 3110
2024
Q4 		$4.18M Sell
741,179
-306,887
-29% -$1.73M ﹤0.01% 3628
2024
Q3 		$5.07M Sell
1,048,066
-240,183
-19% -$1.4M ﹤0.01% 3328
2024
Q2 		$6.29M Buy
1,288,249
+457,379
+55% +$2.87M ﹤0.01% 2945
2024
Q1 		$11M Buy
830,870
+357,254
+75% +$4.74M ﹤0.01% 2379
2023
Q4 		$6.6M Buy
473,616
+268,079
+130% +$3.32M ﹤0.01% 2913
2023
Q3 		$2.73M Sell
205,537
-61,541
-23% -$991K ﹤0.01% 3517
2023
Q2 		$5.01M Buy
267,078
+4,135
+2% +$68.9K ﹤0.01% 3105
2023
Q1 		$3.79M Sell
262,943
-131,291
-33% -$2.57M ﹤0.01% 3317
2022
Q4 		$7.63M Buy
394,234
+90,881
+30% +$2.41M ﹤0.01% 2816
2022
Q3 		$10.4M Buy
303,353
+228,594
+306% +$7.3M ﹤0.01% 2463
2022
Q2 		$1.14M Sell
74,759
-31,609
-30% -$490K ﹤0.01% 4510
2022
Q1 		$2.43M Buy
106,368
+53,968
+103% +$1.54M ﹤0.01% 4079
2021
Q4 		$1.93M Buy
52,400
+10,246
+24% +$430K ﹤0.01% 4284
2021
Q3 		$1.98M Sell
42,154
-76,359
-64% -$4.49M ﹤0.01% 4204
2021
Q2 		$7.14M Buy
+118,513
New +$4.92M ﹤0.01% 3022

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Goldman Sachs's VERV Position: Q3 2025 in Review

Goldman Sachs sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,482,642 shares — an estimated $16.7M sold.

Goldman Sachs first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $16.7M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Goldman Sachs reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,482,642 Verve Therapeutics shares in Q3 2025, an estimated $16.7M.
  • Goldman Sachs first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Goldman Sachs's Verve Therapeutics position peaked at $16.7M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.